mash semaglutide The UK's MRHA has approved a injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) - Novo Nordisk Practical Considerations for the Use

These results suggest that increased plasma serotonin may contribute to regulation of postprandial glucose metabolism, potentially via effects to increase both GLP-1 and insulin secretion

The weight loss data confirm that continued treatment beyond 48 weeks produces additional weight reduction: The 28.7% at 68 weeks exceeds the 24.2% at 48 weeks from Phase 2, representing approximately 4.5 additional percentage points of weight loss over the additional 20 weeks of treatment

Quantitative nutritional studies with water-soluble, chemically defined diets

The bigger picture: GLP-1 therapies are driving innovation at the intersection of endocrinology, cardiology, and obesity managementand reshaping pharma pipelines globally